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hemolytic uremic syndrome.
Background. Thrombotic microangiopathy is the fundamental
lesion in diarrhea-associated hemolytic uremic syndrome. The
extent of the lesion in the renal parenchyma determines the
severity and outcome of the disorder, bilateral renal cortical
necrosis being the worst end of the spectrum. In the early years,
intravascular coagulation was considered the most important
pathogenic mechanism. Yet, individual coagulation factors were
normal in the vast majority of patients and therapy with antico-
agulants did not alter the course. Recent studies indicate that
impaired fibrinolysis might be of importance.
Methods. We studied seven variables of the coagulation path-
way (PT, aPTT, fibrinogen, FVIII:c, von Willebrand factor,
thrombin-antithrombin complexes, prothrombin fragments 112)
and seven parameters of the fibrinolytic system (plasminogen,
alpha2-antiplasmin, C1-esterase inhibitor, tissue-type plasmino-
gen activator, urokinase-type plasminogen activator, plasminogen
activator inhibitor type 1, D-dimer) in 24 pediatric patients with
diarrhea-associated hemolytic uremic syndrome and in 15 chil-
dren with acute renal failure not due to hemolytic uremic
syndrome. Samples were collected at diagnosis and every second
day thereafter for a period of ten days. Additional samples were
collected from patients who underwent dialysis, that is, before and
after each session from those subjected to hemodialysis and every
day from those subjected to peritoneal dialysis. The obtained data
were compared with data from a control group consisting of
healthy children.
Results. Our data show four important features. (1) A signifi-
cant increase in both thrombin-antithrombin complexes (P ,
0.005) and prothrombin fragments 1 1 2 (P , 0.001) is observed
in hemolytic uremic patients as compared to patients with acute
renal failure of other causes. This finding is clearly indicative for
an activation of the coagulation pathway. (2) Patients with the
hemolytic uremic syndrome have significantly higher D-dimer
levels, a sensitive marker of fibrin-specific fibrinolysis, as com-
pared to patients with acute renal failure of other causes (P ,
0.005). (3) Levels of plasminogen activator inhibitor-1 (active
antigen as well as plasminogen activator inhibitor-1 activity) are
not different in both patient groups. In contrast, plasma levels of
tissue-type plasminogen activator and urokinase-type plasmino-
gen activator are significantly higher in the hemolytic uremic
patients than in those with acute renal failure of other causes (P ,
0.01 and P , 0.05 respectively). (4) Hemodialysis leads to an
increase in tissue-type plasminogen activator antigen and a de-
crease of plasminogen activator inhibitor-1 activity levels.
Conclusions. Our data demonstrate that in children with diar-
rhea-associated hemolytic uremic syndrome, limited intravascular
coagulation occurs, without evidence of impaired fibrinolysis.
The hemolytic uremic syndrome (HUS) is characterized
by microangiopathic hemolytic anemia, thrombocytopenia
and acute renal dysfunction, however, its pathogenesis is
unclear. Toxin-induced endothelial injury is the primary
event in diarrhea-associated HUS. This endothelial dam-
age leads to fibrin formation [1] and platelet activation [2].
However, neither anticoagulant therapy nor antiplatelet
medication clearly improves the final prognosis [3]. The
characteristic thrombotic obstruction of glomerular capil-
laries, considered the most likely cause of the acute renal
injury, has been recently attributed to a decreased fibrino-
lysis [4–7]. However, it should be realized that in these
studies no unequivocal conclusions could be drawn due to
the use of inadequate methods for the evaluation of
plasminogen activator inhibitor type 1 (PAI-1) levels (an-
tigen or activity). Indeed, the antigen assays available to
these authors did not discriminate between PAI-1 originat-
ing from plasma (mainly active) and PAI-1 originating from
platelets (mainly latent) [8–10]. The alternative methods
used to evaluate PAI-1 activity, are well known to suffer
from a lack of specificity [11]. In addition, all studies
published to date have been unable to convincingly dem-
onstrate that the reported findings were specific for HUS.
In various case reports HUS patients have been treated
with fibrinolytic agents [12–14]. However, to our knowl-
edge, only one prospective randomized trial has been
carried out to study the effect of fibrinolytic therapy in
HUS patients, and this study was unable to prove the
efficacy of urokinase in HUS [15].
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We have performed a prospective study to better under-
stand the interaction between coagulation and fibrinolysis
at the onset, during the course and in the recovery phase of
the hemolytic uremic process. Specific assays were used to
measure active PAI-1 antigen [16] and specific PAI-1
activity [17]. We also studied the effects of dialysis proce-
dures on coagulation and fibrinolysis in these patients. To
verify whether the observed differences in coagulation
and/or fibrinolytic variables were specific to HUS or merely
associated with acute renal failure, we included pediatric
patients with other causes of acute renal failure (ARF). An
age-matched group of healthy children served as controls.
METHODS
Patients and controls
Between September 1992 and February 1996, 24 infants
and children with diarrhea-associated HUS were admitted
to the Department of Pediatrics. Their median age was
three years (range 9 months to 10 years six months) and
there were 11 girls. They all presented with acquired
non-immune hemolysis, thrombocytopenia and a variable
degree of renal failure. Patients were given a supportive
treatment, including dialysis when necessary. Children un-
der three years of age underwent peritoneal dialysis, and
the older ones hemodialysis. The peritoneal dialysis was
performed for at least the first 12 days, using a commercial
dialysis solution (Baxter, G174 lactate buffer). During the
first three days, the exchanges were performed on a con-
tinuous basis with a one hour dwell time; thereafter, the
dwell time increased to two hours and in one patient the
frequency of exchange decreased to five times daily. The
volume of exchange ranged between 20 and 35 ml/kg body wt.
During the same time period, 13 children (2 girls) were
hospitalized for acute renal failure not due to HUS: acute
glomerulonephritis (N 5 5), prerenal failure (N 5 3), acute
tubulointerstitial nephritis (N 5 2), leukemic infiltration of
the kidney (N 5 1), postrenal failure (N 5 1) and acute on
chronic renal failure (N 5 1). This ARF group had a median
age of seven years (range 9 months to 17 years eight months).
Because coagulation and fibrinolysis variables can be age-
dependent, we included also 14 healthy children with a
median age of two years seven months (range 2 months to 6
years 10 months) among whom six girls. This control group
did not differ significantly in age from the HUS patients.
Study design
Blood samples of the patients were taken on the day of
admission and every other day thereafter for a total dura-
tion of 10 days. Patients on peritoneal dialysis were studied
every day as long as the dialysis lasted. From patients on
hemodialysis, blood was taken before and at the end of
each dialysis session. Blood samples were taken either from
a peripheral vein or from a central venous catheter that was
not heparinized.
Analytical methods
The blood was collected in glass tubes containing 3.8%
trisodium citrate (1 vol citrate plus 9 vol blood) for
determination of the prothrombin time (PT), activated
partial thromboplastin time (aPTT), factor VIII coagulant
activity (FVIII:c), von Willebrand antigen, fibrinogen, D-
dimer, thrombin-antithrombin (TAT) complexes, pro-
thrombin fragments 1 1 2 (F1 1 2), plasminogen, alpha2-
antiplasmin and C1-esterase inhibitor. Another blood
sample was collected in plastic tubes, containing a mixture
of anticoagulant (110 mM sodium citrate) and platelet
inhibitors (15 mM theophylline, 3.7 mM adenosine and 0.198
mM dipyridamole), for determination of tissue-type plas-
minogen activator (t-PA), urokinase-type plasminogen ac-
tivator (u-PA), PAI-1 antigen and PAI-1 activity.
Platelet poor plasma was obtained by centrifugation at
1500 g for 15 minutes and plasma samples were snap-frozen
until assayed.
A standard one-stage clotting assay using a human factor
VIII deficient plasma as substrate was used for the deter-
mination of FVIII:c. Von Willebrand antigen was deter-
mined using an ELISA [18]. Fibrinogen content was de-
rived from the clotting curve [19].
TAT complexes and F1 1 2 were quantified by a
commercially available ELISA (Enzygnost-TAT and En-
zygnost-F1 1 2, Behringwerke, Marbug, Germany).
Plasminogen, alpha2-antiplasmin and C1-esterase inhib-
itor were quantified by an amidolytic assay (Chromogen-
ics). Tissue type-PA antigen [20], u-PA antigen [21] and
D-dimer [22] were determined with ELISA’s as described
previously. Also, PAI-1 antigen (active 1 latent form) [9]
and active PAI-1 antigen [16] were quantified using an
ELISA, whereas PAI-1 activity was measured using an
immuno-functional assay [17]. No other inhibitors can
interfere in the latter activity assay since it is based upon
the specific immunological quantitation of PAI-1/t-PA
complexes formed upon addition of an excess t-PA to the
samples. The characteristics and the validation of this assay
and of the PAI-1 antigen (active 1 latent) assay have been
described elsewhere [9, 17]. In the ELISA for active PAI-1
antigen, using the monoclonal antibodies MA-19A6 and
MA-9E4 [16], latent PAI-1 antigen has a reactivity of only
2.9% 6 1% relative to the reactivity of active antigen. The
intra-assay, inter-assay and interdilution coefficients of
variation of this assay in plasma were 12%, 10%, and 10%,
respectively.
The three PAI-1 assays were further studied using
plasma samples (obtained from 20 healthy individuals)
prepared according to three different procedures: (i) pre-
pared under very strict conditions avoiding any activation
of platelets (collected on CTAD, followed by immediate
processing at 4°C); (ii) prepared under less stringent con-
ditions (on citrate pH 7.5, left at room temperature for a
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few hours before processing at 4°C); and finally (iii) pre-
pared under very loose conditions, allowing platelets to
release latent PAI-1 (collected on CTAD, followed by
transfer to the clinical laboratory to the hospital on room
temperature, where it was further processed as a regular
sample without any precaution). The results of this valida-
tion are given in Table 1.
Statistics
All data are expressed as median values and ranges. The
Wilcoxon signed rank test for pairs was used to validate the
different sample procedures in each PAI-1 assay, to com-
pare the different PAI-1 assays in a limited number of HUS
patients on admission and to analyze pre- and post-dialysis
values in the group of patients treated with hemodialysis.
The significance of differences between controls, HUS and
ARF patients was determined using the Kruskal-Wallis
test. For studying TAT values, this non-parametric test for
censored data were used. When two groups were com-
pared, the Mann-Whitney rank test was applied. To eval-
uate whether any of these variables correlated with the
severity of the HUS, these variables were studied between
two groups (severe vs. non-severe) and interpreted with the
Mann-Whitney rank test. In all statistical analyses, P val-
ues , 0.05 were considered significant.
RESULTS
All HUS and ARF patients survived, one HUS patient
went into chronic renal failure. Of the 24 HUS patients, 10
were hemodialyzed and 3 received peritoneal dialysis.
On admission
Coagulation. Table 2 summarizes the results of the
coagulation variables and von Willebrand factor on admis-
sion. There was no difference in PT and FVIII:c between
the three groups. The aPTT was significantly shorter in
HUS as compared to controls. Fibrinogen was increased in
the HUS group as compared to controls, probably as an
acute phase protein. Von Willebrand factor antigen was
increased both in HUS and ARF as compared to controls,
but no difference was observed between both groups of
patients. However, TAT complexes were significantly
higher in the HUS group (median 33 mg/liter) as compared
to the ARF group (6.7 mg/liter) and the controls (3.0
mg/liter). Similarly, F112 were significantly higher in HUS
patients (median 2.20 nmol/liter) as compared to ARF
patients (1 nmol/liter) and controls (0.5 nmol/liter).
Fibrinolysis. In a first approach to measure PAI-1 antigen
in these patients, the nonspecific assay was used measuring
both the latent and active form. In 154 samples from the
first 18 patients (HUS and ARF) a median value of 58
ng/ml was obtained. When focusing on the samples on
admission, 13 HUS patients showed a median value of 43
(range 15 to 173) ng/ml with the nonspecific PAI-1 antigen
assay, compared to 6 (3.5 to 15.1) ng/ml with the active
PAI-1 antigen assay and 6.4 (3.4 to 16.1) ng/ml with the
PAI-1 activity assay. In this limited patient group the results
of the total PAI-1 antigen differed significantly from the
results of the active PAI-1 antigen assay (P , 0.0005) and
with the results of the PAI-1 activity assay (P , 0.0005),
whereas the results from the active PAI-1 antigen assay and
PAI-1 activity assay did not differ significantly. We there-
fore continued with the specific assays only.
Table 3 shows the variables of the fibrinolytic pathway on
admission. Plasminogen and C1-esterase inhibitor were
similar in all three groups. Significantly lower alpha2-
antiplasmin levels were found in HUS and ARF, as com-
pared to controls, but no difference was observed between
both groups of patients. The fibrinolytic components t-PA
and u-PA were significantly increased in HUS as compared
Table 1. Validation of PAI-1 assays (median and ranges)
Procedure I II III Significance
Total PAI-1 antigen 98 (10–240) 218 (66–338) 632 (210–1210) P , 0.0005; II and III vs. I
Active PAI-1 antigen 96 (18–228) 83 (26–231) 104 (44–280) NS
PAI-1 activity 71 (12–286) 69 (18–238) 83 (12–327) NS
NS, not significant; PAI-1, plasminogen activator inhibitor type 1. Values are expressed as percentage of the mean value obtained in series I with
respective method. Wilcoxon signed rank test for pairs was used.
Table 2. Hemostasis in healthy children and patients with hemolytic uremic syndrome (HUS) and acute renal failure (ARF)
Control HUS ARF HUS vs. ARF HUS vs. control ARF vs. control
PT % 93 (54–100) 82 (32–100) 75 (15–100) NS NS NS
aPTT seconds 37 (31–59) 33 (21–50) 35 (29–.180) NS P , 0.05 NS
Fibrinogen g/liter 2.61 (1.37–5.93) 3.35 (2.02–8.7) 3.91 (0.99–9.35) NS P , 0.05 NS
Factor VIII:c % 101 (49–147) 99 (39–239) 116 (29–208) NS NS NS
von Willebrand % 108 (63–191) 213 (101–446) 155 (75–472) NS P , 0.001 P , 0.05
TAT mg/liter 3.0 (2.0–.60) 33 (2.7–.60) 6.70 (1.9–.60) P , 0.005 P , 0.001 NS
F112 nmol/liter 0.5 (0.2–3.2) 2.20 (0.9–9.6) 1.0 (0.4–6.2) P , 0.001 P , 0.001 P , 0.05
Data are median (ranges). Abbreviations are: NS, not significant; HUS, hemolytic uremic syndrome; ARF, acute renal failure not due to HUS; PT,
prothrombin time; aPTT, activated partial thromboplastin time; TAT, thrombin-antithrombin complexes; F112, prothrombin fragments 112.
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to both ARF and controls; however, active PAI-1 antigen
was comparable in all three groups. PAI-1 activity as
measured by the immunofunctional assay was significantly
elevated in HUS (median 5.9 ng/ml) and in ARF (4.4
ng/ml) compared to controls, but this activity did not differ
between both groups of patients. D-dimer levels were
significantly higher in HUS patients (median 2187 ng/ml) as
compared to ARF patients (588 ng/ml) and to the control
group (216 ng/ml). D-dimer levels of ARF patients were
increased as compared to healthy children.
No difference could be observed in PAI-1 antigen or
PAI-1 activity between HUS patients who needed dialysis
(N 5 13) and those who recovered without dialysis (N 5
11). In contrast, D-dimer levels were significantly higher in
HUS patients requiring dialysis (Fig. 1).
During the course of HUS
Figure 2 illustrates the evolution of active PAI-1 antigen
levels during the course of the disease in HUS patients.
Patients on peritoneal dialysis showed higher levels than
patients treated with hemodialysis and those without dial-
ysis. PAI-1 activity showed a similar pattern (data not
shown).
Effect of hemodialysis
Ten HUS patients received a total of 30 hemodialysis
procedures. Samples taken before and at the end of each
session showed a small but significant increase in t-PA, and
a small but significant decrease in PAI-1 activity (Table 4).
Active PAI-1 antigen levels remained unchanged.
DISCUSSION
Diarrhea-associated hemolytic uremic syndrome
(D1HUS) is the most common cause of acute renal failure in
childhood. The acute mortality is about 5%. Long-term
studies, however, show that another 20% of former HUS
patients have important late sequelae [23, 24]. A deeper
insight in the pathophysiology of the disorder might be helpful
in finding better ways for treatment than the current merely
conservative management.
D1HUS is caused by Shiga-like toxins produced by
micro-organisms mainly from the E.coli species. These
Fig. 1. Active plasminogen activating inhibitor-
1 (PAI-1) antigen (PAI-AG), PAI-1 activity
(PAI-AC) and D-dimer levels in hemolytic
uremic syndrome (HUS) patients who needed
dialysis (A) and in HUS patients who did not
need dialysis (B). Data represent values of
samples taken before any treatment was started.
Table 3. Fibrinolysis in healthy children and patients with HUS and ARF (median and ranges)
Control HUS ARF HUS vs. ARF HUS vs. control ARF vs. control
Plasminogen % 109 (74–134) 96 (67–151) 92 (54–116) NS NS NS
Alpha2-antiplasmin % 118 (108–120) 96 (75–110) 100 (77–113) NS P , 0.001 P , 0.005
t-PA ng/ml 1.5 (0.6–3.1) 5.4 (1.1–10.9) 2.3 (1.2–7.6) P , 0.01 P , 0.001 P , 0.05
u-PA ng/ml 0.58 (0.28–1.20) 1.24 (0.5–4.5) 0.72 (0.3–1.36) P , 0.05 P , 0.001 NS
C1-esterase inhibitor % 120 (106–146) 130 (97–192) 122 (103–184) NS NS NS
PAI-1 activity ng/ml 1.2 (0–9.3) 5.9 (1–53.6) 4.4 (0.8–88.6) NS P , 0.001 P , 0.005
Active PAI-1 antigen ng/ml 7.9 (4–25.8) 7.5 (3.5–58.2) 10.4 (3.4–45.6) NS NS NS
D-dimer ng/ml 261 (238–320) 2266 (216–17824) 588 (150–1551) P , 0.005 P , 0.001 P , 0.005
Abbreviations are: NS, not significant; HUS, hemolytic uremic syndrome; ARF, acute renal failure not due to HUS; t-PA, tissue-type plasminogen
activator; u-PA, urokinase-type plasminogen activator; PAI-1, plasminogen activator inhibitor type 1.
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toxins cause damage to the arteriolar endothelium. The
kidney appears to be the major target, most likely because
of its high density of small arteries. Endothelial damage
leads to platelet adhesion and aggregation and subse-
quently results in thrombocytopenia, one of the hallmarks
of HUS. Kidney biopsy and autopsy documents of patients
who died in the early phase of the disease invariably show
glomerular thrombi formation and fibrin deposition [1, 25].
These findings can be summarized as thrombotic microan-
giopathy.
While studies on coagulation variables in childhood HUS
have shown essentially normal values [26], recent studies
using modern and sensitive laboratory methodology are
scanty. Therefore, in the current study we have evaluated
seven variables of the hemostasis pathway in detail in
children with HUS and compared the obtained data with
those obtained from an age-matched control group. To
distinguish between changes (that is, HUS vs. healthy
control) arising from acute renal failure in general or
typically associated with HUS patients, a control group
composed of pediatric patients with non-HUS related ARF
was also included. Surprisingly, the aPTT was shorter in
HUS patients as compared to the control group. We are at
present unable to explain the etiology of this difference
because, for example, factor IX:c, factor XI and factor XII
were not measured. TAT-complexes and F112 were signif-
icantly higher in HUS than in ARF patients. This clearly
indicates that definite, albeit limited, intravascular coagu-
lation takes place in this disorder, and this is in agreement
with histological findings as described above.
Using a bio-assay, Bergstein et al demonstrated an
inhibitory effect of HUS-plasma on fibrinolysis in 1982 [27].
They also treated rabbits suffering from the generalized
Schwartzman reaction after endotoxin injection, with t-PA
and found less fibrin deposition in the kidney of the t-PA
treated group [28]. More recently, Bergstein et al studied
the fibrinolytic system in children with D1HUS [5]. Three
conclusions were drawn: (i) PAI-1 levels are elevated in
HUS; (ii) peritoneal dialysis is able to normalize the plasma
levels of this inhibitor of fibrinolysis; and (iii) a correlation
was found between PAI-1 levels and outcome, namely, the
higher the PAI-1 levels, the worse the outcome. Yet, it is
important to realize that PAI-1 can occur in a latent form
as well as in an active form and that platelets constitute
;90% of total PAI-1 antigen in blood. Platelet PAI-1 is
mainly in the latent conformation whereas plasma PAI-1 is
mainly in the active form [10]. Thus, in this view, the
methodology available to Bergstein et al at that time was
not really appropriate [5]. Indeed, the immunological
method to quantify PAI-1 antigen was sensitive to active
PAI-1 as well as latent PAI-1 (that is, PAI-1 from plasma as
well as platelet PAI-1). It is obvious that in a disorder with
thrombocytopenia due to intense platelet activation, a huge
amount of latent PAI-1 is released from platelet granules in
the circulation, thereby interfering with the antigen measure-
ments. This increased platelet consumption in HUS was
already demonstrated by Chong et al, who found elevated
Fig. 2. Active PAI-1 antigen level (median
values), in HUS patients without dialysis (E,
N 5 11), on hemodialysis before the dialysis
(F, N 5 10) and in 2 patients on peritoneal
dialysis (, ) during the course of the HUS.
For patients without dialysis and those on
hemodialysis, the levels at the day of admission
and thereafter the mean of every two
consecutive days, if both values were available,
were studied.
Table 4. t-PA and PAI-1 levels before (pre) and after (post)
hemodialysis
Prea Posta Difference P valueb
t-PA 4.6 5.5 0.9 , 0.02
Active PAI-1 antigen 6.5 6.8 0.3 NS
PAI-1 activity 5.5 4.7 20.8 , 0.02
Abbreviations are: NS, not significant; t-PA, tissue-type plasminogen
activator; PAI-1, plasminogen activator inhibitor type 1.
a Values represent mean values (N 5 30) and are expressed in ng/ml
b Wilcoxon test (Methods section)
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plasma levels of P-selectin and beta-thromboglobulin in these
patients [29]. To analyze the plasma samples obtained from
our first 18 patients, we used a similar assay sensitive to
both active and latent PAI-1 antigen [9], and indeed found
highly elevated levels, comparable with those reported by
Bergstein et al [5]. This inspired us to use more appropriate
methods specific for active PAI-1 only (that is, reflecting
levels of PAI-1 from plasmatic origin, irrespective of plate-
let activation). Using this specific method [16], no increase
in active PAI-1 antigen levels in the HUS-patients could be
observed, indicating that the previously reported excess in
PAI-1 antigen had originated from platelets. Bergstein et al
also utilized a functional assay to study fibrinolysis inhibi-
tion [5], but it is well-known that this type of assay is not
specific for PAI-1, nor does it give accurate information on
the in vivo fibrinolytic state in these patients.
Four other groups also measured PAI-1 in patients with
HUS and reported increased levels [4, 6, 7, 30]. Chant,
Milfors and Rose could correlate higher PAI activity with
severity of disease and with a poor outcome at one year
[30]. However, these study methods also suffer from the
above-mentioned shortcomings. Therefore, again it can be
stated that the observed increase in PAI-1 was related to
platelet activation and not specifically related to the under-
lying condition. Importantly, these authors also failed to
include adequate controls, that is, patients with acute renal
failure not related to HUS. Our current study clearly
demonstrates that this is a crucial issue. Indeed, the levels
of PAI-1 activity, the main inhibitor of fibrinolysis, are
increased in HUS compared to healthy children, but a
similar increase is observed in the group of children with
acute renal failure due to other illnesses, clearly demon-
strating that this increase is not HUS-specific.
Our findings not only fail to confirm that the fibrinolytic
system is depressed in HUS, they demonstrate a stimula-
tion of fibrinolysis. Indeed, the increased t-PA and u-PA
levels suggest activation of the fibrinolytic system. This
activation is further clearly illustrated by the observation of
significantly increased levels of D-dimer in HUS patients
compared to healthy controls and ARF patients.
The absence of a direct role of PAI-1 (neither causative,
nor prognostic) in HUS is further demonstrated by the
observation that the severity of HUS in our patients is not
associated with increased levels of PAI-1. Moreover, the
elevated D-dimer levels in the more severe group of HUS
patients (Fig. 1) suggests a more active fibrinolysis in this
group of patients. In addition, we were unable to confirm
the salutary effect of peritoneal dialysis as found by Berg-
stein et al [5]. We cannot exclude that the absence of a
salutary effect is due to a different procedure of dialysis. In
contrast, hemodialysis seems to be beneficial in that it
increases t-PA and decreases PAI-1.
Even though there is no obvious explanation for the
lower alpha2-antiplasmin levels in the HUS and the ARF
patients as compared to controls, this observation is in
accordance with data of Goos, Declercq and Proesmans
[31], who found decreased levels of alpha2-globulins in the
acute phase of HUS.
Regarding fibrinolysis/coagulation and final outcome, we
had only one HUS patient out of 24 who developed chronic
renal failure (data not shown). This patient exhibited very
high D-dimer levels (12144 ng/ml), TAT complexes (.60
mg/liter), F112 (9.6 nM), as well as von Willebrand antigen
(446%), but relatively low levels of PAI-1 activity (3 ng/ml)
and active PAI-1 antigen (6.08 ng/ml). These data add
further to our hypothesis that HUS (and ultimately a
negative outcome) is associated with both an increased
coagulation and fibrinolysis.
Since in none of the above-mentioned studies nor in the
current study, was the etiology of D1HUS defined, it
cannot be excluded that the differences observed between
the different reports might, at least in part, be related to
differences in the etiology of the disease.
In conclusion, our study provides evidence for limited
intravascular coagulation in children with D1HUS, but no
evidence for HUS-specific impaired fibrinolysis. Even
though, based on previous studies reporting impaired fibri-
nolysis, systemic administration of fibrinolytic agents in
HUS patients has been suggested, our findings clearly do
not support such a therapeutic intervention in HUS pa-
tients.
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APPENDIX
Abbreviations used in this article are: aPTT, activated partial thrombo-
plastin time; ARF, acute renal failure not due to HUS; D1HUS,
diarrhea-associated hemolytic uremic syndrome; F112, prothrombin frag-
ments; FVIII:c, factor VIII coagulant activity; HUS, hemolytic uremic
syndrome; PAI-1, plasminogen activator inhibitor type 1; PT, prothrombin
time; TAT, thrombin-antithrombin; t-PA, tissue-type plasminogen activa-
tor; u-PA, urokinase-type plasminogen activator.
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